Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-04-11FDA Approved: PREMARIN — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for Premarin (conjugated estrogens) filed by Wyeth Pharmaceuticals, a Pfizer subsidiary. The submiss…
-
FDA approval · 2012-03-19FDA Approved: IBANDRONATE SODIUM — Original Application (Apotex Corp)
FDA approved the original application for ibandronate sodium by Apotex Corp, enabling a generic version of the osteoporosis treatment.
-
FDA approval · 2012-03-19FDA Approved: IBANDRONATE SODIUM — Original Application (Bionpharma Inc.)
FDA approved the original generic application for ibandronate sodium by Bionpharma Inc., enabling a generic version of the osteoporosis trea…
-
FDA approval · 2012-03-13FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2012-03-02Clinical Trial Update: Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women [Phase 4]
Phase 4 clinical trial update comparing teriparatide and zoledronic acid for bone outcomes in postmenopausal women with osteoporosis, with r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-02-17Clinical Trial Update: Risedronate in Postmenopausal Women With Low Bone Density [Phase 2]
Phase 2 trial of risedronate in postmenopausal women with low bone density has completed.
-
FDA approval · 2012-02-02FDA Approved: PREMPRO — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for PREMPRO (conjugated estrogens and medroxyprogesterone acetate) submitted by Wyeth Pharmaceutical…
-
CLINICAL_TRIALS trial_result · 2012-01-13Clinical Trial Update: Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate [Phase 2]
Phase 2 study assessing the safety, efficacy, and pharmacokinetics of immediate and delayed-release weekly risedronate in postmenopausal wom…
-
CLINICAL_TRIALS trial_result · 2012-01-09Clinical Trial Update: Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling [NA]
An open-label clinical study evaluating MBP-80 on bone remodeling in postmenopausal osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2011-12-23Clinical Trial Update: Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women [Phase 3]
A Phase 3 trial in postmenopausal osteoporosis has completed and assessed bone microstructure in patients treated with nasal salmon calciton…
-
CLINICAL_TRIALS trial_result · 2011-11-11Clinical Trial Update: A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide [Phase 4]
A Phase 4 study used imaging to measure changes in bone structure after treatment with teriparatide in postmenopausal osteoporosis; results …
-
FDA approval · 2011-10-28FDA Approved: CONJUGATED ESTROGENS — Supplemental Application (Prasco Laboratories)
FDA has approved a supplemental NDA for Conjugated Estrogens (Estrogens, Conjugated) from Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2011-10-26Clinical Trial Update: Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover [Phase 3]
Phase 3 trial evaluating the impact of stopping risedronate after long-term treatment on bone turnover in postmenopausal osteoporosis; resul…
-
CLINICAL_TRIALS trial_result · 2011-10-12Clinical Trial Update: Food Effects on the Relative Bioavailability of Different Dosages of Risedronate [Phase 1]
Phase 1 study assessing how meals affect the relative bioavailability of various doses of risedronate in postmenopausal women. The trial sta…
-
CLINICAL_TRIALS trial_result · 2011-09-28Clinical Trial Update: Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO [Phase 3]
Phase 3 study evaluating bone mineral density and bone turnover response to 5 mg daily risedronate in women with postmenopausal osteoporosis…
-
FDA approval · 2011-08-22FDA Approved: ACTONEL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Actonel (risedronate sodium) by Allergan, Inc.
-
FDA approval · 2011-08-22FDA Approved: ATELVIA — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for Atelvia (risendronate sodium), resulting in an approved label-related update for the pr…
-
CLINICAL_TRIALS trial_result · 2011-08-11Clinical Trial Update: Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women [Phase 3]
Phase 3 trial evaluating the efficacy and safety of menatetrenone for postmenopausal osteoporosis has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2011-08-11Clinical Trial Update: Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women [Phase 2]
Phase 2 trial evaluating whole-body vibration as an add-on treatment for osteoporosis in postmenopausal women has completed, reporting safet…
-
FDA approval · 2011-08-10FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide filed by Prasco Laboratories, expanding the regulatory status of the product un…
-
CLINICAL_TRIALS trial_result · 2011-08-10Clinical Trial Update: Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation [Phase 2]
This Phase 2 trial update reports dose–response results for lasofoxifene in postmenopausal osteoporosis, focusing on a Japanese/Asian popula…
-
CLINICAL_TRIALS trial_result · 2011-08-10Clinical Trial Update: The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation [Phase 2]
Completed Phase 2 trial evaluating lasofoxifene for prevention of postmenopausal osteoporosis, including cytokine assessments.
-
CLINICAL_TRIALS trial_result · 2011-07-28Clinical Trial Update: A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab [Phase 3]
Phase 3 imaging study update using high-resolution peripheral quantitative computed tomography in postmenopausal women previously treated wi…
-
FDA approval · 2011-07-07FDA Approved: ALENDRONATE SODIUM — Supplemental Application (EXELAN PHARMACEUTICALS INC.)
FDA approved a supplemental application for alendronate sodium submitted by Exelan Pharmaceuticals.
-
FDA approval · 2011-07-01FDA Approved: FOSAMAX PLUS D — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Fosamax Plus D (alendronate sodium and cholecalciferol) by Organon LLC.